UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO

Their core work

UPO is an Italian university based in Vercelli (Piedmont) with strong research capabilities in nanosafety science, regenerative medicine, and biomaterials engineering. Their teams develop nanobiomaterial-based therapies for musculoskeletal repair, design organ-on-chip platforms for personalized medicine, and assess the safety and toxicology of nanomaterials using computational and omics-based methods. They also contribute to emergency medical systems and pre-hospital care technologies, and have a growing portfolio in environmental risk assessment of emerging pollutants like PFAS.

What they specialise in

How they've shifted over time

In the early H2020 period (2014–2018), UPO focused heavily on science communication, public engagement, and responsible research activities alongside foundational work in nanosafety and catalysis. From 2019 onward, a sharp pivot is visible toward biomedical applications — cartilage regeneration, personalized medicine, organ-on-chip technologies, and precision therapies using 3D bioprinting and nanobiomaterials. Their most recent projects (2021) also show growing investment in computational nanosafety (nanoinformatics, safe-by-design) and environmental hazard assessment of PFAS, suggesting a convergence of their nano-expertise with both medical and environmental applications.

UPO is consolidating around the intersection of nanomaterials, biomedicine, and computational safety — expect future work in organ-on-chip diagnostics, nano-enabled therapies, and AI-driven hazard assessment.

How they like to work

UPO balances coordination and participation roughly 1:3, coordinating 6 out of 21 projects — a high rate for a mid-sized university, indicating genuine leadership capacity rather than passive participation. With 286 unique consortium partners across 39 countries, they operate as a well-connected hub rather than a loyal-partner type, comfortable building new consortia for each project. Their coordinated projects tend to be mid-budget RIA and MSCA actions (EUR 700K–1.25M), suggesting they are effective at managing focused research consortia rather than mega-projects.

UPO has collaborated with 286 distinct partners across 39 countries, giving them one of the broader networks for a university of their size. Their reach spans all of Europe with connections extending well beyond the EU, though Italian and Western European partners likely form the core.

What sets them apart

UPO occupies a distinctive niche at the crossroads of nanosafety science and regenerative medicine — few European universities combine deep expertise in nanomaterial risk assessment with hands-on development of nano-enabled biomedical therapies. Their dual capability means they can both develop nanobiomaterial-based treatments AND assess their safety within the same institution, which is valuable for consortia building regulatory-ready medical technologies. Their coordinated SCENARIOS project (EUR 1.25M) on PFAS risk assessment also positions them as a go-to partner for emerging pollutant challenges.

Highlights from their portfolio

• SCENARIOS
  UPO's largest project (EUR 1.25M as coordinator), tackling PFAS pollution with integrated testing and new approach methodologies — a high-priority regulatory topic across Europe.
• FLAMIN-GO
  Coordinated by UPO, this project builds synovia-on-chip microfluidic platforms for rheumatoid arthritis, representing their push into precision medicine and organ-on-chip technology.
• HemAcure
  Their highest single-project funding (EUR 1.4M as participant), developing an implantable gene-and-cell therapy device — showcasing their capacity to contribute to ambitious translational biomedical research.